RxDoctor Payments Data

Tracey Respess

Nurse Practitioner · Chocowinity, NCNPI 1548474463

Payments from drug & device makers

$1,547in general payments, 2019–2025

Across 83 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$267
  • Lilly USA, LLC$225
  • AstraZeneca$164
  • Pfizer$156
  • Abbott$128
  • Merck$110
  • plus $497 from 12 others

What the payments were for

  • Food & beverage$1,547100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,547 in reported general payments places this provider in the 80th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$46,054
Medicare patients
164
Services billed
1,673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$66,733
EliquisApixaban44$37,485
XareltoRivaroxaban16$12,437
Janumet XrSitagliptin Phos/Metformin Hcl14$11,418
MyrbetriqMirabegron16$8,499
FarxigaDapagliflozin Propanediol13$8,475
JanumetSitagliptin Phos/Metformin Hcl13$7,059
Levemir FlexpenInsulin Detemir30$6,860
Gabapentin157$2,611
Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm15$2,600
Dabigatran EtexilateDabigatran Etexilate Mesylate12$1,950
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$1,929
Celecoxib87$1,641
Duloxetine Hcl106$1,482
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst44$1,473

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$267$66,73362 claims
PfizerEliquis$156$37,48544 claims
MerckJanumet Xr, Janumet$110$18,47727 claims
Astellas Pharma US IncMyrbetriq$41$8,49916 claims
AstraZenecaFarxiga$164$8,47513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Chocowinity

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →